Skip to main content
Top
Published in: Pathology & Oncology Research 3/2020

01-07-2020 | Colorectal Cancer | Short Communication

Tight Junction-Related CLDN5 and CLDN6 Genes, and Gap Junction-Related GJB6 and GJB7 Genes Are Somatically Mutated in Gastric and Colorectal Cancers

Authors: Hyun Ji Son, Chang Hyeok An, Nam Jin Yoo, Sug Hyung Lee

Published in: Pathology & Oncology Research | Issue 3/2020

Login to get access

Abstract

Tight junction and gap junction are major cell junctions that play important roles in cellular communication and structural integrity. Alterations of these junctions are known to be involved in cancer pathogenesis. Claudins and connexins are major tight and gap junction proteins, but genetic alterations of these genes have not been reported in gastric (GC) and colorectal cancers (CRC) with microsatellite instability (MSI). Claudin genes CLDN5 and CKDN6, and connexin genes GJB6 and GJB7 have mononucleotide repeats in the coding sequences that might be mutation targets in the cancers with MSI. We analyzed 79 GCs and 145 CRCs, and found CLDN5 frameshift mutations in 3 (3%) CRCs and 1 (2.9%) GC, CLDN6 frameshift mutations in 6 (6%) CRCs, GJB6 frameshift mutations in 5 (5%) CRCs and GJB7 frameshift mutation in one CRC (1%) with high MSI (MSI-H). We also analyzed intratumoral heterogeneity (ITH) of the frameshift mutations in 16 CRCs and found that CLDN6 and GJB6 frameshift mutations showed regional ITH in 2 (12.5%) and 2 (12.5%) cases, respectively. Our results show that CLDN5, CLDN6, GJB6 and GJB7 genes harbor not only frameshift mutations but also mutational ITH, which together may be features of GC and CRC with MSI-H. Based on the roles of cellular junctions in cancers, frameshift mutations of tight junction and gap junction genes might contribute to tumorigenesis by altering their functions in GC and CRC.
Literature
1.
go back to reference Trosko JE, Ruch RJ (1998) Cell-cell communication in carcinogenesis. Front Biosci 3:d208–236CrossRef Trosko JE, Ruch RJ (1998) Cell-cell communication in carcinogenesis. Front Biosci 3:d208–236CrossRef
2.
go back to reference Holder JW, Elmore E, Barrett JC (1993) Gap junction function and cancer. Cancer Res 53:3475–3485PubMed Holder JW, Elmore E, Barrett JC (1993) Gap junction function and cancer. Cancer Res 53:3475–3485PubMed
3.
go back to reference Martin TA, Mason MD, Jiang WG (2011) Tight junctions in cancer metastasis. Front Biosci 16:898–936CrossRef Martin TA, Mason MD, Jiang WG (2011) Tight junctions in cancer metastasis. Front Biosci 16:898–936CrossRef
4.
go back to reference Imai K, Yamamoto H (2008) Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29:673–680CrossRef Imai K, Yamamoto H (2008) Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 29:673–680CrossRef
5.
go back to reference Murphy K, Zhang S, Geiger T, Hafez MJ, Bacher J, Berg KD, Eshleman JR (2006) Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 8:305–311CrossRef Murphy K, Zhang S, Geiger T, Hafez MJ, Bacher J, Berg KD, Eshleman JR (2006) Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 8:305–311CrossRef
6.
go back to reference Choi EJ, Kim MS, Song SY, Yoo NJ, Lee SH (2017) Intratumoral heterogeneity of frameshift mutations in MECOM Gene is frequent in colorectal cancers with high microsatellite instability. Pathol Oncol Res 23:145–149 Choi EJ, Kim MS, Song SY, Yoo NJ, Lee SH (2017) Intratumoral heterogeneity of frameshift mutations in MECOM Gene is frequent in colorectal cancers with high microsatellite instability. Pathol Oncol Res 23:145–149
7.
go back to reference Bujko M, Kober P, Mikula M, Ligaj M, Ostrowski J, Siedlecki JA (2015) Expression changes of cell-cell adhesion-related genes in colorectal tumors. Oncol Lett 9:2463–2470CrossRef Bujko M, Kober P, Mikula M, Ligaj M, Ostrowski J, Siedlecki JA (2015) Expression changes of cell-cell adhesion-related genes in colorectal tumors. Oncol Lett 9:2463–2470CrossRef
8.
go back to reference Gao F, Li M, Xiang R, Zhou X, Zhu L, Zhai Y (2019) Expression of CLDN6 in tissues of gastric cancer patients: association with clinical pathology and prognosis. Oncol Lett 17:4621–4625 Gao F, Li M, Xiang R, Zhou X, Zhu L, Zhai Y (2019) Expression of CLDN6 in tissues of gastric cancer patients: association with clinical pathology and prognosis. Oncol Lett 17:4621–4625
9.
go back to reference Sirnes S, Honne H, Ahmed D, Danielsen SA, Rognum TO, Meling GI, Leithe E, Rivedal E, Lothe RA, Lind GE (2011) DNA methylation analyses of the connexin gene family reveal silencing of GJC1 (Connexin45) by promoter hypermethylation in colorectal cancer. Epigenetics 6:602–609CrossRef Sirnes S, Honne H, Ahmed D, Danielsen SA, Rognum TO, Meling GI, Leithe E, Rivedal E, Lothe RA, Lind GE (2011) DNA methylation analyses of the connexin gene family reveal silencing of GJC1 (Connexin45) by promoter hypermethylation in colorectal cancer. Epigenetics 6:602–609CrossRef
10.
go back to reference Sentani K, Oue N, Sakamoto N, Anami K, Naito Y, Aoyagi K, Sasaki H, Yasui W (2010) Upregulation of connexin 30 in intestinal phenotype gastric cancer and its reduction during tumor progression. Pathobiology 77:241–248CrossRef Sentani K, Oue N, Sakamoto N, Anami K, Naito Y, Aoyagi K, Sasaki H, Yasui W (2010) Upregulation of connexin 30 in intestinal phenotype gastric cancer and its reduction during tumor progression. Pathobiology 77:241–248CrossRef
Metadata
Title
Tight Junction-Related CLDN5 and CLDN6 Genes, and Gap Junction-Related GJB6 and GJB7 Genes Are Somatically Mutated in Gastric and Colorectal Cancers
Authors
Hyun Ji Son
Chang Hyeok An
Nam Jin Yoo
Sug Hyung Lee
Publication date
01-07-2020
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-020-00806-2

Other articles of this Issue 3/2020

Pathology & Oncology Research 3/2020 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine